Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates reduced infarct volume and improved neurological function with interleukin-11 therapy in mice, indicating therapeutic potential for ischemic stroke.
Our research suggests that IL-11 is decreased during cerebral ischemia-reperfusion injury, but IL-11 treatment can improve neurological function and reduce the cerebral infarct volume, which can trigger stroke in mice. AMPK inhibition can further promote the protective effect of IL-11 in stroke. Overall, we demonstrate that IL-11 is of therapeutic interest in controlling stroke and managing cerebral ischemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: